Home > Selected Past Studies

SELECTED PAST STUDIES - All Cancers - Breast - Ovarian - Uterine Cancers

Study

Disease

type & number of samples

Specific Requirements

associated data required

BOU-1

Breast Cancer Stage IV

FFPE Blocks

Retrospective

More than 360 subjects

  • 50% Progesterone Receptor-Positive
  • 50% Progesterone Receptor-Negative
  • Stage IV Breast Cancer
  • Demographic, diagnostic data
  • TNM
  • Sample collection date
  • Cold ischemia time
  • ER and Her2 status

BOU-2

Breast Cancer

FFPE Blocks and PBMC

Retrospective

More than 40 subjects

  • Breast Adenocarcinoma
  • Peripheral Blood Mononuclear cells (PBMC), if available
  • Primary tumor tissue only
  • PBMC isolated from 10 mL of blood collected at diagnosis
  • Age, ethnicity
  • Sample collection date
  • Date of diagnosis
  • Confirmed clinical diagnosis
  • Type of treatment
  • Medical Outcome (presence/absence of relapse or death) within 5 years

BOU-3

Breast Cancer

FFPE Blocks

Retrospective

More than 10 subjects

  • Triple-Negative Breast Cancer

Primary tumor tissue only 2 FFPE blocks:

  • One pre-chemotherapy
  • One post-chemotherapy
  • Demographic, diagnostic data
  • TNM
  • Sample collection date
  • Treatment history and overall survival data

BOU-4

Breast Cancer

FFPE Blocks

Retrospective

More than 20 subjects

  • Invasive Breast Cancer Any stage, Grade 1 or 2
  • Tissue biopsies
  • Demographic, diagnostic data
  • TNM
  • Sample collection date

BOU-5

Breast Cancer

Fresh Frozen Tissue

Prospective

More than 12 subjects

  • Triple-Negative Breast Cancer (TNBC)
  • Any stage
  • Age, ethnicity
  • Height, weight
  • Current treatment
  • Concurrent diseases
  • Pathology Report

BOU-6

Breast Cancer

Fresh Frozen Lymph Nodes

Retrospective

More than 270 subjects

3 groups:

  • Breast Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Lymph node weight > 50 mg
  • Demographic, diagnostic data
  • TNM
  • Sample collection date
  • Lymph Node weight

BOU-7

Breast Cancer

Whole Blood

Prospective

More than 30 subjects

3 groups:

  • Breast Cancer
  • Gastric Cancer
  • Control (Healthy) Subjects
  • Subjects with stage III or IV cancer
  • Blood collected at time of diagnosis prior to any treatment or between treatment cycles
  • Whole blood samples must be collected on specific Tubes
  • Age, gender, ethnicity
  • Sample collection date
  • Date of diagnosis
  • Confirmed clinical diagnosis

BOU-8

Ovarian Cancer Cervical Cancer

FFPE Blocks

Retrospective

More than 6 subjects

2 groups:

  • 50% Ovarian Transitional Carcinoma
  • 50% Cervical Small Cell Carcinoma 
  • Any stage
  • Demographic, diagnostic data
  • TNM
  • Sample collection date

BOU-9

Ovarian Cancer

Fresh Tissue

Prospective

More than 4 subjects with Primary Ovarian Cancer

  • Freshly resected tissue
  • Any subtype
  • Samples must be received fresh within 24 hours of resection
  • Demographic, diagnostic data
  • TNM
  • Sample collection date
  • Treatment History

BOU-10

Ovarian Cancer

Serum

Retrospective

More than 160 subjects

4 groups:

  • Non-Cancerous Ovarian Disease
  • Early Stage Ovarian Cancer (Stage I)
  • Aggressive Ovarian Cancer (Stage III or IV) with a survival less than 5 years from diagnosis
  • Non-Aggressive Ovarian Cancer (Stage III or IV) with a survival more than 5 years from diagnosis.
  • Samples stored at -80oC
  • No freeze-thaw cycle
  • Demographic, diagnostic data
  • TNM
  • Sample collection date
  • Treatment History